News

PRX-07034 is the fourth novel drug candidate from Preix’ drug discovery platform to progress into human clinical trials. It is a novel, highly selective, small-molecule antagonist of a

INCB13739 is an orally available small molecule inhibitor of 11-beta hydroxysteroid dehydrogenase type 1 (11beta-HSD1), an enzyme that appears to be critical to the development of type 2

The discovery by researchers in Hopkins’ Institute of Basic Biomedical Sciences and McKusick-Nathans Institute for Genetic Medicine reveals that a protein called GCN5 is critical for controlling a

In preclinical models, a new formulation of the angiotensin vaccine containing CoVaccine’s adjuvant resulted in a tenfold higher level of antibody production against angiotensin than the formulation previously

The study evaluated treatment of about 300 patients who had severe chronic heart failure despite traditional treatment. They were studied in three groups, two of which were treated

Aspreva is currently evaluating CellCept for the treatment of pemphigus vulgaris (PV) in a global phase III study. The randomized, double-blind, placebo-controlled comparison study is investigating the efficacy

The company said that its global clinical operations (GCO) unit will establish this global set of standards, policies and practices, and build a management system that will oversee

Under the agreement, Human Genome Sciences (HGS) and Novartis will co-commercialize Albuferon in the US, and will share costs and profits equally. Outside of the US, Novartis will

In addition, Gilead has entered into long-term agreements with Degussa for the supply of raw materials and the manufacture of certain active pharmaceutical ingredients (API) for Gilead products.